Perrault syndrome 5

disease
On this page

Also known as Perrault syndrome caused by mutation in TWNKPerrault syndrome type 5PRLTS5TWNK Perrault syndrome

Summary

Perrault syndrome 5 (MONDO:0014504) is a disease caused by TWNK (GenCC Definitive), with 1 cohort gene.

At a glance

  • Causal gene: TWNK (GenCC Definitive)
  • Cohort genes: 1
  • ClinVar variants: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namePerrault syndrome 5
Mondo IDMONDO:0014504
OMIM616138
UMLSC4015307
MedGen863744
GARD0016062
Is cancer (heuristic)no

Also known as: Perrault syndrome 5 · Perrault syndrome caused by mutation in TWNK · Perrault syndrome type 5 · PRLTS5 · TWNK Perrault syndrome

Data availability: 24 ClinVar variants · 2 GenCC gene-disease records · 1 cell line.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive diseasePerrault syndromePerrault syndrome 5

Related subtypes (6): Perrault syndrome 1, Perrault syndrome 3, Perrault syndrome 2, Perrault syndrome 4, Perrault syndrome 6, Perrault syndrome 7

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

24 retrieved; paginated sample, class counts are floors:

11 conflicting classifications of pathogenicity, 6 uncertain significance, 4 likely pathogenic, 2 pathogenic, 1 pathogenic/likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
162049NM_021830.5(TWNK):c.1754A>G (p.Asn585Ser)TWNKPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
162050NM_021830.5(TWNK):c.1321T>G (p.Trp441Gly)TWNKPathogeniccriteria provided, single submitter
3377475NM_021830.5(TWNK):c.742_745del (p.Phe248fs)TWNKPathogeniccriteria provided, single submitter
3382359NM_021830.5(TWNK):c.1399C>T (p.Gln467Ter)TWNKLikely pathogeniccriteria provided, single submitter
3601957NM_021830.5(TWNK):c.42del (p.Leu14fs)TWNKLikely pathogeniccriteria provided, single submitter
4619NM_021830.5(TWNK):c.1422G>A (p.Trp474Ter)TWNKLikely pathogeniccriteria provided, single submitter
4820080NM_021830.5(TWNK):c.1278_1279del (p.Ser426fs)TWNKLikely pathogeniccriteria provided, single submitter
1309254NM_021830.5(TWNK):c.193C>T (p.Arg65Trp)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1344254NM_021830.5(TWNK):c.478C>T (p.Arg160Ter)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1497932NM_021830.5(TWNK):c.1618G>A (p.Gly540Arg)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
162048NM_021830.5(TWNK):c.1172G>A (p.Arg391His)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
162051NM_021830.5(TWNK):c.1519G>A (p.Val507Ile)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1683933NM_021830.5(TWNK):c.1958C>T (p.Ser653Phe)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
214174NM_021830.5(TWNK):c.737A>G (p.Asn246Ser)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
214178NM_021830.5(TWNK):c.1975G>A (p.Ala659Thr)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
488187NM_021830.5(TWNK):c.874C>A (p.Pro292Thr)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
694394NM_021830.5(TWNK):c.793C>T (p.Arg265Cys)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
878940NM_021830.5(TWNK):c.1597G>A (p.Ala533Thr)TWNKConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1312836NM_021830.5(TWNK):c.1338C>G (p.Ile446Met)TWNKUncertain significancecriteria provided, multiple submitters, no conflicts
1441023NM_021830.5(TWNK):c.602C>T (p.Ala201Val)TWNKUncertain significancecriteria provided, multiple submitters, no conflicts
1496673NM_021830.5(TWNK):c.1190A>G (p.Asp397Gly)TWNKUncertain significancecriteria provided, multiple submitters, no conflicts
2960437NM_021830.5(TWNK):c.1817C>G (p.Ser606Cys)TWNKUncertain significancecriteria provided, multiple submitters, no conflicts
3590126NM_021830.5(TWNK):c.250T>G (p.Phe84Val)TWNKUncertain significancecriteria provided, single submitter
878124NM_021830.5(TWNK):c.-592C>TTWNKUncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 10 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
TWNKDefinitiveAutosomal recessivePerrault syndrome 510

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TWNKOrphanet:1186Infantile-onset spinocerebellar ataxia
TWNKOrphanet:254892Autosomal dominant progressive external ophthalmoplegia
TWNKOrphanet:363534Mitochondrial DNA depletion syndrome, hepatocerebrorenal form
TWNKOrphanet:642945Perrault syndrome type 1
TWNKOrphanet:642976Perrault syndrome type 2
TWNKOrphanet:70595Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TWNKHGNC:1160ENSG00000107815Q96RR1Twinkle mtDNA helicasegencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TWNKTwinkle mtDNA helicaseMitochondrial helicase involved in mtDNA replication and repair.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Enzyme (other)112.0×0.083

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TWNKEnzyme (other)yes3.6.4.12DNA_helicase_DnaB-like_C, Twinkle-like, P-loop_NTPase

Expression context

Cohort genes with no expression data: 0.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
gastrocnemius1
male germ line stem cell (sensu Vertebrata) in testis1
tendon of biceps brachii1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TWNK211ubiquitousyesmale germ line stem cell (sensu Vertebrata) in testis, tendon of biceps brachii, gastrocnemius

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TWNK1,390

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
TWNKQ96RR12

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Strand-asynchronous mitochondrial DNA replication11142.0×0.003TWNK
Transcriptional activation of mitochondrial biogenesis1203.9×0.007TWNK
Mitochondrial protein degradation1114.2×0.009TWNK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
mitochondrial transcription12407.4×9e-04TWNK
mitochondrial DNA replication11532.0×9e-04TWNK
protein hexamerization11404.3×9e-04TWNK
DNA-templated DNA replication1561.7×0.002TWNK

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TWNK00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
TWNK3.6.4.12DNA helicase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug1TWNK
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TWNK0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.